The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1691
ISSUE1691
December 11, 2023
Drugs for Depression
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Depression
December 11, 2023 (Issue: 1691)
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR, and
others), and mirtazapine (Remeron, and...more
- American Psychiatric Association. Treating major depressive disorder: a quick reference guide. Based on practice guideline for the treatment of patients with major depressive disorder, third edition, October 2010. Available at http://bit.ly/2GTfF02. Accessed November 21, 2023.
- MN Milosavljevic et al. Mirtazapine-induced acute pancreatitis in patients with depression: a systematic review. J Psychiatr Pract 2023; 29:58. doi:10.1097/pra.0000000000000687
- A Fagiolini et al. Role of trazodone in treatment of major depressive disorder: an update. Ann Gen Psychiatry 2023; 22:32. doi:10.1186/s12991-023-00465-y
- K Waters. The clinical utility of newer antidepressant agents: understanding the role in management of MDD. Mental Health Clin 2022; 12:309. doi:10.9740/mhc.2022.10.309
- Dextromethorphan/bupropion (Auvelity) for depression. Med Lett Drugs Ther 2022; 64:201.
- RL Dean et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev 2021; 9:CD011612. doi:10.1002/14651858.cd011612.pub3
- A Anand et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med 2023; 388:2315. doi:10.1056/nejmoa2302399
- A new indication for esketamine nasal spray (Spravato). Med Lett Drugs Ther 2020; 62:151.
- AK Gill et al. Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties. Drugs Today (Barc) 2019; 55:423. doi:10.1358/dot.2019.55.7.2958474
- S Mohamed et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA 2017; 318:132. doi:10.1001/jama.2017.8036
- EJ Lenze et al. Antidepressant augmentation versus switch in treatment-resistant geriatric depression. N Engl J Med 2023; 388:1067. doi:10.1056/nejmoa2204462
- MB Stein and J Sareen. Clinical practice. Generalized anxiety disorder. N Engl J Med 2015; 373:2059. doi:10.1056/nejmcp1502514
- RS McIntyre et al. Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder. J Clin Psychiatry 2017; 78:703. doi:10.4088/jcp.16cs10885
- GH Vasquez et al. Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium. J Psychopharmacol 2021; 35:890. doi:10.1177/02698811211013579
- A Reif et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med 2023; 389:1298. doi:10.1056/nejmoa2304145
- R Jain et al. Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD. CNS Spectr 2020; 25:750. doi:10.1017/s1092852919001469
- A Al Maruf et al. Systematic review and meta-analysis of L-methylfolate augmentation in depressive disorders. Pharmacopsychiatry 2022; 55:139. doi:10.1055/a-1681-2047
- RC Shelton. St. John’s wort (Hypercum perforatum) in major depression. J Clin Psychiatry 2009; 70 (suppl 5):23. doi:10.4088/jcp.8157su1c.05
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- GM Goodwin et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 2022; 387:1637. doi:10.1056/nejmoa2206443
- CL Raison et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 2023; 330:843. doi:10.1001/jama.2023.14530
- SB Gumusoglu et al. Selective serotonin reuptake inhibitors and preeclampsia: a quality assessment and meta-analysis. Pregnancy Hypertens 2022; 30:36. doi:10.1016/j.preghy.2022.08.001
- KF Huybrechts et al. Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. BMJ 2020; 368:m237. doi:10.1136/bmj.m237
- CM Morrison. A case report of the use of vilazodone in pregnancy. Prim Care Companion CNS Disord 2014; 16:PCC.13l01612. doi:10.4088/pcc.13l01612
- S Shweiki and O Diav-Citrin. Pregnancy outcome after first trimester exposure to vortioxetine: a case series. Birth Defects Res 2021; 113:511. doi:10.1002/bdr2.1864
- SV Carlini et al. Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression. Dialogues Clin Neurosci 2023; 25:92. doi:10.1080 /19585969.2023.2262464
- Brexanolone (Zulresso) for postpartum depression. Med Lett Drugs Ther 2019; 61:68.
- CN Epperson et al. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression; pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J Affect Disord 2023; 320:353. doi:10.1016/j.jad.2022.09.143
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. November 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth.com/drug-pricing-policy.
- KM Deligiannidis et al. Zuranolone for the treatment of postpartum depression. Am J Psychiatry 2023; 180:668. doi:10.1176/appi.ajp.20220785
- Zuranolone (Zurvuvae) – an oral drug for postpartum depression. Med Lett Drugs Ther 2023. In press.
- J Ekstrand et al. Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT). Int J Neuropsychopharmacol 2022; 25:339. doi:10.1093/ijnp/pyab088
- TG Rhee et al. Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and metaanalysis. JAMA Psychiatry 2022; 79:1162. doi:10.1001/jamapsychiatry.2022.3352
- Health Quality Ontario. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. Ont Health Technol Assess Ser 2016; 16:1.
- IO Bergfeld. Deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2016; 73:456. doi:10.1001/jamapsychiatry.2016.0152
- DD Dougherty. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biol Psychiatry 2015; 78:240. doi:10.1016/j.biopsych.2014.11.023
- CA Bousman et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther 2023; 114:51. doi:10.1002/cpt.2903
- X Wang et al. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT. BMC Psychiatry 2023; 23:334. doi:10.1186/s12888-023-04756-2
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Depression
Article code: 1691a
Article code: 1691a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.